CN106573154B - 中和抗乙型流感抗体及其用途 - Google Patents

中和抗乙型流感抗体及其用途 Download PDF

Info

Publication number
CN106573154B
CN106573154B CN201580038244.1A CN201580038244A CN106573154B CN 106573154 B CN106573154 B CN 106573154B CN 201580038244 A CN201580038244 A CN 201580038244A CN 106573154 B CN106573154 B CN 106573154B
Authority
CN
China
Prior art keywords
antibody
influenza
antigen
binding fragment
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580038244.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN106573154A (zh
Inventor
大卫·柯蒂
安东尼奥·兰扎韦基亚
N.卡勒瓦德-勒莱
朱青
E.本加明
L.瓦奇特
袁清安
J.M.麦克奥利夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
MedImmune Vaccines Inc
Original Assignee
Humabs Biomed SA
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA, MedImmune LLC filed Critical Humabs Biomed SA
Priority to CN202410982380.7A priority Critical patent/CN119161468A/zh
Priority to CN202110634379.1A priority patent/CN113563462B/zh
Priority to CN202110634430.9A priority patent/CN113173990B/zh
Publication of CN106573154A publication Critical patent/CN106573154A/zh
Application granted granted Critical
Publication of CN106573154B publication Critical patent/CN106573154B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C07K16/108—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201580038244.1A 2014-07-15 2015-07-14 中和抗乙型流感抗体及其用途 Active CN106573154B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202410982380.7A CN119161468A (zh) 2014-07-15 2015-07-14 中和抗乙型流感抗体及其用途
CN202110634379.1A CN113563462B (zh) 2014-07-15 2015-07-14 中和抗乙型流感抗体及其用途
CN202110634430.9A CN113173990B (zh) 2014-07-15 2015-07-14 中和抗乙型流感抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462024804P 2014-07-15 2014-07-15
US62/024804 2014-07-15
PCT/US2015/040385 WO2016011035A2 (en) 2014-07-15 2015-07-14 Neutralizing anti-influenza b antibodies and uses thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202110634430.9A Division CN113173990B (zh) 2014-07-15 2015-07-14 中和抗乙型流感抗体及其用途
CN202410982380.7A Division CN119161468A (zh) 2014-07-15 2015-07-14 中和抗乙型流感抗体及其用途
CN202110634379.1A Division CN113563462B (zh) 2014-07-15 2015-07-14 中和抗乙型流感抗体及其用途

Publications (2)

Publication Number Publication Date
CN106573154A CN106573154A (zh) 2017-04-19
CN106573154B true CN106573154B (zh) 2021-06-15

Family

ID=55079157

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201580038244.1A Active CN106573154B (zh) 2014-07-15 2015-07-14 中和抗乙型流感抗体及其用途
CN202410982380.7A Pending CN119161468A (zh) 2014-07-15 2015-07-14 中和抗乙型流感抗体及其用途
CN202110634430.9A Active CN113173990B (zh) 2014-07-15 2015-07-14 中和抗乙型流感抗体及其用途
CN202110634379.1A Active CN113563462B (zh) 2014-07-15 2015-07-14 中和抗乙型流感抗体及其用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202410982380.7A Pending CN119161468A (zh) 2014-07-15 2015-07-14 中和抗乙型流感抗体及其用途
CN202110634430.9A Active CN113173990B (zh) 2014-07-15 2015-07-14 中和抗乙型流感抗体及其用途
CN202110634379.1A Active CN113563462B (zh) 2014-07-15 2015-07-14 中和抗乙型流感抗体及其用途

Country Status (9)

Country Link
US (6) US10294292B2 (enExample)
JP (4) JP6837434B2 (enExample)
CN (4) CN106573154B (enExample)
AU (3) AU2015289805B2 (enExample)
BR (1) BR112017000640A2 (enExample)
CA (1) CA2954780A1 (enExample)
MX (3) MX392761B (enExample)
RU (2) RU2739952C2 (enExample)
WO (1) WO2016011035A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201602522VA (en) * 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
CN106573154B (zh) 2014-07-15 2021-06-15 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
DK3303384T3 (da) 2015-06-01 2021-10-18 Medimmune Llc Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf
KR20250130692A (ko) 2016-01-13 2025-09-02 메디뮨 엘엘씨 인플루엔자 a의 치료 방법
BR112022007923A2 (pt) * 2019-10-28 2022-07-26 Regeneron Pharma Anticorpo recombinante isolado ou fragmento de ligação ao antígeno deste, composição farmacêutica, molécula de polinucleotídeo, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma da infecção por influenza
CN112048006B (zh) * 2020-09-08 2021-04-27 扬州大学 一种替代中和效力测定的elisa方法及其应用
US20250320279A1 (en) * 2021-11-30 2025-10-16 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof
CN118420751B (zh) * 2022-07-09 2025-04-08 东莞市朋志生物科技有限公司 抗乙型流感病毒抗体、检测乙型流感病毒的试剂和试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013086052A2 (en) * 2011-12-05 2013-06-13 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
WO2013132007A1 (en) * 2012-03-08 2013-09-12 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
CN103906763A (zh) * 2011-07-14 2014-07-02 克鲁塞尔荷兰公司 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US6027459A (en) 1996-12-06 2000-02-22 Abbott Laboratories Method and apparatus for obtaining blood for diagnostic tests
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
JP4528989B2 (ja) * 1999-03-31 2010-08-25 学校法人慶應義塾 インフルエンザウイルス・ヘマグルチニン結合性ペプチド
EP1264885A4 (en) 2000-02-22 2007-02-21 Med & Biological Lab Co Ltd ANTIBODY LIBRARY
ES2330330T3 (es) 2000-06-28 2009-12-09 Glycofi, Inc. Procedimiento de produccion de glucoproteinas modificadas.
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2004001007A2 (en) 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
AU2003251809A1 (en) 2002-07-11 2004-02-02 The General Hospital Corporation Polynucleotide and polypeptide fat metabolism regulators and uses thereof
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
RU2366662C2 (ru) 2003-07-23 2009-09-10 Фуджирибайо Инк. Моноклональное антитело к вирусу типа а гриппа и устройство для иммунного анализа с использованием антитела
AU2004263037B2 (en) 2003-08-11 2011-02-10 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Novel vaccine containing adjuvant capable of inducing mucosal immunity
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005056759A2 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
PT2532679T (pt) 2005-10-21 2017-07-18 Novartis Ag Anticorpos humanos contra il13 e utilizações terapêuticas
KR20080094918A (ko) 2006-01-17 2008-10-27 바이오렉스 쎄라퓨틱스, 인코포레이티드 식물에서 ｎ-글리칸의 인간화 및 최적화 조성물 및 방법
CA2647380A1 (en) 2006-03-21 2007-09-27 David T. Weaver Methods for humanizing antibodies and humanized antibodies made thereby
WO2007117577A2 (en) 2006-04-07 2007-10-18 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-18 receptor
CA2652452C (en) 2006-05-15 2018-07-31 Sea Lane Biotechnologies, Llc Neutralizing antibodies to influenza viruses
US8192927B2 (en) 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
JP2010505418A (ja) 2006-10-02 2010-02-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−４受容体に対する高親和性ヒト抗体
EP2094307A4 (en) 2006-11-08 2015-08-26 Macrogenics West Inc TES7 AND THEREO BINDING ANTIBODIES
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
JP5346820B2 (ja) 2007-03-13 2013-11-20 エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
NZ590890A (en) 2008-07-25 2013-05-31 Inst Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
EP4071169A2 (en) 2008-08-25 2022-10-12 Dana Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US9534042B2 (en) * 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
AU2011344126B2 (en) 2010-12-13 2016-11-10 The University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
CA2841551C (en) 2011-07-18 2020-07-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2013043729A1 (en) 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
CN103957891B (zh) 2011-09-23 2017-01-11 美利坚合众国由健康及人类服务部部长代表 基于流感血凝素蛋白的新颖疫苗
JP2014533249A (ja) * 2011-11-07 2014-12-11 メディミューン，エルエルシー 多重特異性を持つ多価結合タンパク質およびその使用
CA2890669A1 (en) 2012-11-13 2014-05-22 Genetech, Inc. Anti-hemagglutinin antibodies and methods of use
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
RU2536956C1 (ru) 2013-08-05 2014-12-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства" Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
CN106573154B (zh) 2014-07-15 2021-06-15 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
DK3303384T3 (da) 2015-06-01 2021-10-18 Medimmune Llc Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf
KR20250130692A (ko) 2016-01-13 2025-09-02 메디뮨 엘엘씨 인플루엔자 a의 치료 방법
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103906763A (zh) * 2011-07-14 2014-07-02 克鲁塞尔荷兰公司 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子
WO2013086052A2 (en) * 2011-12-05 2013-06-13 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
WO2013132007A1 (en) * 2012-03-08 2013-09-12 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Highly Conserved Protective Epitopes on Influenza B Viruses;Cyrille Dreyfus;《SCIENCE》;20120809;第337卷(第6100期);第1343页摘要,第1344页图1-2 *

Also Published As

Publication number Publication date
RU2017104638A (ru) 2018-08-15
US20250263470A1 (en) 2025-08-21
US11174304B2 (en) 2021-11-16
RU2020100073A3 (enExample) 2020-06-10
JP6837434B2 (ja) 2021-03-03
EP3169407A4 (en) 2018-04-25
CA2954780A1 (en) 2016-01-21
MX392761B (es) 2025-03-21
US20170218054A1 (en) 2017-08-03
JP7453430B2 (ja) 2024-03-19
AU2024202231A1 (en) 2024-05-02
AU2015289805B2 (en) 2020-06-25
JP2017523805A (ja) 2017-08-24
CN113563462A (zh) 2021-10-29
WO2016011035A2 (en) 2016-01-21
BR112017000640A2 (pt) 2017-11-14
RU2739952C2 (ru) 2020-12-30
US20240076357A1 (en) 2024-03-07
RU2711932C2 (ru) 2020-01-23
CN106573154A (zh) 2017-04-19
US12325740B2 (en) 2025-06-10
US20200190169A1 (en) 2020-06-18
RU2017104638A3 (enExample) 2019-07-17
WO2016011035A3 (en) 2016-03-10
US10294292B2 (en) 2019-05-21
CN113173990B (zh) 2024-10-29
MX2022006561A (es) 2022-07-11
CN113563462B (zh) 2024-08-13
MX2022006558A (es) 2022-07-11
JP2021074013A (ja) 2021-05-20
US20190233504A1 (en) 2019-08-01
JP2023052268A (ja) 2023-04-11
RU2020100073A (ru) 2020-03-03
JP7209754B2 (ja) 2023-01-20
WO2016011035A8 (en) 2016-12-08
JP2024069341A (ja) 2024-05-21
CN119161468A (zh) 2024-12-20
US11787853B2 (en) 2023-10-17
AU2020233635B2 (en) 2024-01-18
US20220025020A1 (en) 2022-01-27
EP3169407A2 (en) 2017-05-24
CN113173990A (zh) 2021-07-27
AU2015289805A1 (en) 2017-03-02
US10519221B2 (en) 2019-12-31
MX2017000595A (es) 2017-10-12
AU2020233635A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
RU2683498C2 (ru) Нейтрализующие антитела к вирусу гриппа а и пути их применения
JP7453430B2 (ja) 抗ｂ型インフルエンザ抗体の中和及びその使用
RU2784915C2 (ru) Нейтрализующие антитела к вирусу гриппа b и пути их применения
HK40061870A (en) Neutralizing anti-influenza b antibodies and uses thereof
HK40057425A (en) Neutralizing anti-influenza b antibodies and uses thereof
HK40064533A (en) Neutralizing anti-influenza a antibodies and uses thereof
HK40064536A (en) Neutralizing anti-influenza a antibodies and uses thereof
HK40061870B (zh) 中和抗乙型流感抗体及其用途
HK40057425B (zh) 中和抗乙型流感抗体及其用途
RU2803850C2 (ru) Нейтрализующие антитела к вирусу гриппа а и пути их применения
HK40120900A (zh) 中和抗乙型流感抗体及其用途
HK40110292A (zh) 中和抗甲型流感抗体及其用途
HK40064536B (zh) 中和抗甲型流感抗体及其用途
HK40064533B (zh) 中和抗甲型流感抗体及其用途
HK1227788A1 (en) Neutralizing anti-influenza a antibodies and uses thereof
HK1227788B (zh) 中和抗甲型流感抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right

Effective date of registration: 20170621

Address after: American Maryland

Applicant after: Medimmune Vaccines Inc.

Applicant after: HUMABS BIOMED SA

Address before: American Maryland

Applicant before: Medimmune Vaccines Inc.

Applicant before: David Kodi

Applicant before: Antonio Lanzavecchia

TA01 Transfer of patent application right
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant